R&D channel feed

Im­munomedics spells out PFS ben­e­fit of Trodelvy in mTNBC, hunt­ing a full OK just weeks af­ter ac­cel­er­at­ed ap­proval

5 years ago
Pharma

Ob­sE­va’s sec­ond uter­ine fi­broids PhI­II comes through, send­ing some in­vestors to the hills

5 years ago

Bel­lus hit with a set­back as its PhII chron­ic cough drug flops on all 4 dos­es — shares cre­mat­ed on Wall Street

5 years ago

De­vel­op­ment part­ners at MEI, Helsinn dump a high-risk PhI­II AML study af­ter con­clud­ing it would fail sur­vival goal

5 years ago

Io­n­is, lead­ing MS re­searcher throw an­ti­sense at a new type of brain cells

5 years ago
Cell/Gene Tx

Pfiz­er shares surge on pos­i­tive im­pact of their mR­NA Covid-19 vac­cine — part­nered with BioN­Tech — in an ear­ly-stage study

5 years ago
Coronavirus

Bolt Bio­ther­a­peu­tics nabs $93.5M to push Provenge in­ven­tor's new idea deep­er in the clin­ic

5 years ago
Financing

Days af­ter In­ter­cept re­jec­tion, Akero surges on ‘un­prece­dent­ed‘ NASH da­ta

5 years ago

Covid-19 has roiled clin­i­cal tri­al plans around the world, rais­ing con­cerns over the in­dus­try’s fu­ture on new drug ap­provals

5 years ago
Coronavirus

An ex­pe­ri­enced biotech is stitched to­geth­er from transpa­cif­ic parts, with 265 staffers and a fo­cus on ‘new bi­ol­o­gy’

5 years ago
Deals
Pharma

Elias Zer­houni dis­cuss­es ‘am­a­teur hour’ in DC, the de­struc­tion of in­fec­tious dis­ease R&D and how we need to prep for the next time

5 years ago
People
Pharma

Zyner­ba flunks an­oth­er ma­jor tri­al, all but end­ing Frag­ile X hopes

5 years ago

Pos­i­tive Covid-19 vac­cine da­ta? New mouse study? OWS in­clu­sion? Yep, but some­how, the usu­al tid­bits from In­ovio back­fire

5 years ago
Bioregnum
Opinion

Take­da maps out a dis­cov­ery al­liance aimed at break­ing through the safe­ty and ef­fi­ca­cy bound­aries that lim­it the first-gen gene ther­a­pies

5 years ago
Financing
Discovery

Seat­tle Ge­net­ics, Gen­mab turn on TV for a high­light reel in cer­vi­cal can­cer — but a ri­val biotech promis­es a bet­ter show

5 years ago

FDA re­jects In­ter­cept’s pitch for NASH as CEO fires back at the agency’s ‘evolv­ing’ guide­lines

5 years ago
FDA+

Kiniksa preps BLA as Re­gen­eron drug cruis­es to a PhI­II win — shares soar

5 years ago

Sec­ond death trig­gers hold on Astel­las' $3B gene ther­a­py biotech's lead pro­gram, rais­ing fresh con­cerns about AAV

5 years ago
Cell/Gene Tx

Pre­sent­ed with up­beat Alzheimer's ag­i­ta­tion da­ta, FDA sees an­oth­er 'break­through' in Ax­some's AXS-05

5 years ago
FDA+

Over a decade ago, a dis­as­trous tri­al killed re­search on a po­ten­tial im­munother­a­py. Can a Re­gen­eron bis­pe­cif­ic re­vive it?

5 years ago

FDA OKs Mer­ck’s heavy­weight Keytru­da for can­cer niche — trig­ger­ing ti­tle fight with the street brawlers at Re­gen­eron

5 years ago
FDA+

Sang­amo splits the R from the D in a re­or­ga­ni­za­tion — and bids chief farewell

5 years ago
People

Ac­celeron promised they had great da­ta on so­tater­cept in late Jan­u­ary. But was it good enough to jus­ti­fy a dou­bling of the stock price?

5 years ago

Burned by Alzheimer’s fail­ures, a cau­tious Mer­ck turns to a start­up biotech for some pre­clin­i­cal neu­ro pro­grams

5 years ago
Deals
Discovery
First page Previous page 196197198199200201202 Next page Last page
A service from the Financial Times